UNSPSC 51422437: Tixocortol pivalate

This classification denotes a hydrocortisone analog and 21-thiol hydrocortisone derivative C26H38O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K28E35M3B, chemically known as pregn-4-ene-3,20-dione, 21-((2,2-dimethyl-1-oxopropyl)thio)-11,17-dihydroxy-, (11.beta.)-, but more generally known as tixocortol pivalate, which bears US NIH Compound Identifier 15052414. European Medicines Agency schedules Tixocortol pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04894MIG.

Most nations, for tariff and trade purposes, schedule tixocortol pivalate under HS 29372900 and SITC 54153. As of Q4 2014, TIXOCORTOL PIVALATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CSC(=O)C(C)(C)C)O)C)O.

UNSPSC 51422437 Tixocortol pivalate is a Commodity code that nominally describes a specific corticosteroid pharmaceutical ingredient, but the recent state and local procurement record shows a significant scope mismatch. The single recent opportunity flagged under this code — Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems — concerns opioid-reversal medications and drug disposal equipment, not tixocortol pivalate or dermatological corticosteroid products. This mismatch suggests either a data-tagging error in the state and local procurement system or that the code is being applied to a broader family of pharmaceutical procurement than its name indicates.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building. The response deadline was July 26, 2023 (a date inconsistent with the posting date, likely a data error in the source). Bidders must include shipping and delivery costs, comply with E-Verify and drug-free workplace requirements, maintain specified insurance coverage, and meet federal compliance standards if the contract is FEMA-funded. The code shows minimal recent activity overall, and the single opportunity available does not align clearly with the code's pharmaceutical product definition. Business development professionals should verify the correct UNSPSC code for Naloxone and drug-disposal-system procurement before pursuing this opportunity, as the current code assignment appears to be an error.